drugset / Trial / NCT04785755

Effects of Adding Hypertonic Saline Solutions and/or Etilefrine to Standard Diuretics Therapy in Hepatic Ascites

NCT04785755

Phase 2 Completed 90 enrolled Hala Abd EL-Tawab Ibrahim Radwan
RandomizedParallel-groupOpen-labelTreatment

Summary

This work aimed to evaluate and compare the impact of adding hypertonic saline solution (HSS) infusion and/or etilefrine to oral diuretics therapy on clinical outcomes, renal and systemic hemodynamics, metabolic and inflammatory pathways by estimating the changes in selected biological markers in cirrhotic patients with ascites. Also, the trial aims to assess the safety and tolerability of such treatment regimens.

Timeline

Start
2017-11-30
Primary completion
2020-03-21
Completion
2020-04-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Etilefrine Small molecule 5 mg Oral
Subject sodium chloride Unknown 1.4 % Other
Subject sodium chloride Unknown 4.6 % Other
Subject sodium chloride Unknown 150 ml Other
Background Furosemide Other / unclassified 40 mg Oral
Background Spironolactone Small molecule 100 mg Oral

Indications

No indication recorded.